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ABSTRACT
INTRODUCTION: The immune response in the Hepatitis B virus (HBV) represents a key factor in the in-
fection outcome. However, the relation between the viral replication and the host immune reactivity is still 
a matter of investigation.
AIM: To investigate whether the cellular immune response of newly diagnosed and treatment naïve chronic 
hepatitis B (CHB) patients may be influenced by the replicative status of HBV.
MATERIALS AND METHODS: A total of 45 (17 female and 28 male) newly diagnosed untreated CHB pa-
tients aged 42.48±13.19 years (19÷71 years) were enrolled in this study. The patients were divided into two 
groups according to the viral load: >0÷≤104 copies/ml (n=25) and >10 4÷<108 copies/ml (n=17). Flow cytomet-
ric immunophenotyping was performed for evaluation of the cellular immunity. Serum HBV DNA load was 
assessed by quantitative real-time polymerase chain reaction.
RESULTS: Similar alterations were observed in both patients’ groups in comparison to the healthy controls. It 
could be summarized as it follows: decreased total T cells (CD3+) due to low helper-inducer (CD3+CD4+) and 
suppressor-cytotoxic (CD3+CD8+) subpopulations; reduced effector cytotoxic (CD8+CD11b-; CD8+CD28+) 
and activated (CD3+HLA-DR+, CD8+CD38+) T-cell subsets; increased CD57+CD8- cells; elevated percent-
age of B lymphocytes. No significant differences in the studied immune parameters were detected between 
both patients’ groups except the significantly elevated CD4/CD8 ratio in individuals with higher in compar-
ison to those with lower HBV DNA levels.
CONCLUSION: Alterations in the cellular immune response of CHB patients were observed resulting main-
ly in significantly decreased T-cell subpopulations, particularly those with effector cell immune phenotype 
regardless of the viral load.
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INTRODUCTION
Hepatitis B virus (HBV) infection is a major 
global public health problem. Of the approximately 
2 billion people who have been infected worldwide, 
more than 350-400 million remain infected chroni-
cally and become carriers of the virus (1). The prev-
alence of HBV infection varies markedly in differ-
ent geographic areas of the world, as well as in dif-
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ferent population subgroups (2). Overall, about 5% 
of the population in Bulgaria is infected with HBV, 
in some districts reaching up to 7% (3), which plac-
es our country among the regions of the world with 
moderate prevalence (2-7%) of the virus but among 
those with higher rates in Europe.
The patient’s immune response is one of the 
major factors influencing the viral eradication or 
chronification of the liver damage. The chronic 
course of HBV infection depends also on the host ge-
netic factors and the virus itself – genotype and vi-
ral load. 
The aim of our study was to investigate wheth-
er the cellular immune response of the newly diag-
nosed and treatment naïve chronic hepatitis B (CHB) 




We investigated 45 (17 female and 28 male) 
treatment naïve patients with chronic viral hepatitis 
B aged 42.48±13.19 years (19÷71 years). All patients 
were referred from the Department of Gastroenterol-
ogy at the Clinic of Propaedeutics of Internal Diseas-
es, University Hospital “Alexandrovska”, Sofia, after 
clinical and laboratory evaluation according to pre-
defined inclusion and exclusion criteria. The diagno-
sis of chronic hepatitis B was based on the recom-
mendations of the American Association for Study of 
Liver Diseases. The results were compared to 29 age- 
and sex-matched healthy volunteers with normal liv-
er function and negative serological markers for viral 
hepatitis. Prior to the evaluation, written informed 
consent for participation in the study was obtained 
from all patients and control subjects.  
Cellular immunity
For the assessment of the cellular immuni-
ty, phenotyping of peripheral blood cells was per-
formed using different combinations of monoclonal 
antibodies. The analysis was done with FACSCan-
to flowcytometer and FACSDiva software (Becton 
Dickinson, USA).
The following immune cells were investigated: 
total Т (CD3+) cells; helper-inducer (CD3+CD4+) 
and suppressor-cytotoxic (CD3+CD8+) T-cell sub-
sets; В (CD19+) and NK (CD3-CD16+56+) cells; T-
lymphocytes at different differentiation stages and 
functional characteristics: effector (cytotoxic and/
or memory T cells - CD8+CD28+), terminally dif-
ferentiated cellular subpopulations with memory/
effector function (CD8+CD28-, CD8+CD57+), cel-
lular populations with cytotoxic (CD8+CD11b-) 
and suppressor (CD8+CD11b+) potential; activat-
ed T-cells (CD3+HLA-DR+, CD8+HLA-DR+ and 
CD8+CD38+); T-lymphocytes with NK activity 
[NKT – CD3+CD(16+56+)].
Viral load 
The quantitative evaluation of viremia was per-
formed using ТaqMan quantitative RT-PCR (Ap-
plied Biosystem Real Time PCR primers and probe; 
Applied Biosystem 7300 RT-PCR system). The meth-
od is based on the detection of fluorescent signal gen-
erated by hydrolysis of a TagMan probe during target 
DNA amplification. For the generation of a reference 
curve four standards (Clonit HBV DNA complete ge-
nome) were used. The high sensitivity of the method 
(98%) allowed determining low hepatitis B viral load 
(≤100 copies/ml).
Statistical analysis
The comparative analysis of the cellular popu-
lations in different groups was performed using para-
metric (Student’s t-test) and non-paramertic (Mann-
Whitney) methods.  The correlation analysis (viral 
load/cellular populations) was done by Spearman’s 
rank correlations. The statistical analysis was per-
formed using SPSS v.16. Values of Р<0.05 were con-
sidered statistically significant.
RESULTS 
According to the viral load the investigated HBV 
patients were divided into two groups: group 1 – vi-
ral load >0 ÷ ≤104 copies/ml (25 patients) and group 
2 – viral load > 104 ÷ ≤ 108 copies/ml (17 patients). No 
patients with extremely high viremia (>108 copies/ml) 
were diagnosed during the study. The results of im-
munophenotyping are presented in Table 1. 
Our data (Table 1) showed similar alterations in 
both groups of patients as compared to healthy con-
trols which could be summarized as it follows:
1. Low values of total T-cells (CD3+) due to 
decreased helper-inducer (CD3+CD4+) 
and suppressor-cytotoxic (CD3+CD8+) 
subpopulations; 
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2. Reduced T-cell subsets with effector cytotoxic 
activity (CD8+CD11b-; CD8+CD28+); 
3. Decreased activated (CD3+HLA-DR+, 
CD8+CD38+) T-cells; 
4. Elevated percentage of B cells.
5. Additionally, individuals with lower vi-
ral load had increased percentages of NKT 
[CD3+(CD16+56+)] and CD8+CD11b+ cells in 
comparison to healthy controls.  
As a whole, no significant differences in the 
studied immune parameters were observed between 
both patients’ groups with the exception of signifi-
cantly higher values of CD4+ T cells and a trend of 
more pronounced reduction of CD8+ T-cell subsets 
in individuals with higher as compared to those with 
lower rate of viral replication. These disturbances 
lead to a markedly higher (p=0.031) CD4/CD8 ratio 
in patients with viral load >104 copies/ml in compar-
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CD4/CD8 1.47±0.35 2.12±1.41 1.65±0.48 0.061 0.566 0.031
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As another approach to test whether the viral 
replication rate could influence the cellular immu-
nity of patients with chronic HBV infection, we have 
performed a correlation analysis between the lev-
el of viremia and the values of the investigated cell 
subsets. No statistically significant correlations were 
found between the HBV replication rate and the cel-
lular immune alterations.
DISCUSSION
In the majority of cases the HBV infection is 
self-limiting due to the fact that effective immune re-
sponses from innate and adaptive immune systems 
can lead to complete clearance of the virus or at least 
to suppression of viral replication. Studies have re-
vealed that T-cellular immune reactivity is essential 
for the disease pathogenesis. Powerful CD8 immune 
response has been proven in patients with spontane-
ous eradication of HBV, and in those with chronic 
disease evolution this reactivity is much weaker or 
absent (4,5,6). Тhe effector cell dysfunction is one of 
the main factors for the chronic evolution of infec-
tion.  Тhe chronic course of the disease is associated 
with multiple defects in T-cellular immunity corre-
lating with the viral replication (7). The higher HBV 
DNA levels inhibit both CD4+ and CD8+ Т-cells (8) 
and these alterations increase the risk for liver dys-
function, disease chronification, liver cirrhosis and 
hepatocellular carcinoma. It should be taken into 
consideration that the interpretation of viral load 
data and comparison of results have been compli-
cated by the inconsistency among the various units 
of measure for HBV DNA and the different criteria 
for grading the level of viral replication. A study in 
India (9) divided the HBV patients into two groups 
according to their viral loads (lower - <2000 IU/ml 
and higher - >2000 IU/ml) and found decreased total 
T-cell counts in both patients’ groups as compared 
to healthy individuals. Additionally, subjects with 
higher viral replication demonstrated a decrease of 
cytotoxic T-cells in comparison to controls, where-
as such differences were not observed in individu-
als with lower HBV DNA levels. Using another ap-
proach for the classification of viral load Xibing et al. 
(10) found elevated numbers of specific cytotoxic T-
lymphocytes and NK cells, and decreased non-spe-
cific cytotoxic T-cell subsets  in the group with low-
er (HBV DNA 104-105 copies/ml) compared to this 
with higher (106-107 copies/ml) rate of viral replica-
tion. You et al. (11,12) described negative correlation 
between the levels of HBV DNA on one hand, and 
CD4+ cells and CD4/CD8 ratio – on the other hand. 
On the contrary, their data revealed positive correla-
tion of CD8+ cells with viral load. 
The results of our study showed no differenc-
es between the two groups of CHB patients (with 
low ≤104 copies/ml and high >104-108 copies/ml vi-
ral DNA levels) concerning the studied cellular im-
mune parameters. In both patients’ groups we ob-
served marked T-cell deficiency. These findings are 
consistent with the results of Mukherjee et al. (9), but 
do not comply with those of others authors (11,12). 
The detailed analysis of T-lymphocytes according to 
differentiation stages and functional characteristics 
revealed decreased cell subpopulations with putative 
cytotoxic potential (CD8+CD11b- and CD8+CD28+) 
in both patients’ groups compared to healthy con-
trols. These results correlate with the reported re-
duced nonspecific cytotoxic T-cells in chronic hepa-
titis B (9). It should be pointed out that Sun et al. (13) 
established increased percentages of CD8+CD28- 
subset in the CD8+ population in CHB correlating 
with the levels of viral DNA. In line with the above 
mentioned observations Li et al. (14) described de-
creased CD8+CD28+/CD8+CD28- T-cells ratio in 
CHB patients compared to healthy controls due to el-
evated values of CD8+CD28- cell subset and associ-
ated with HBV loads. In contrast to the abovemen-
tioned data, no alterations of CD8+CD28- cell sub-
sets in CHB were found by us. A possible explana-
tion of the observed discrepancies could be attribut-
ed to the different approaches of cell subset analysis 
– in the lymphocytes in our study or within the T-
cell population in the other investigations. It is inter-
esting to note the decreased levels of T-cells express-
ing different activation markers (CD3+HLA-DR+, 
CD8+CD38+) found in our HBV positive patients 
(regardless of viral loads) in comparison to healthy 
controls. Cao et al. (15) established significant pos-
itive association between the CD8+CD38+ T-cell 
proportions and serum HBV DNA, while Nikolo-
va et al. (16) reported the lack of such correlation. It 
should be also noted that Ye et al. (17) observed low-
er proportions of activated CD38+ T cells in patients 
with non-recovered acute-on-chronic liver failure 
(ACLFs) (characterized by higher HBV DNA levels) 
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and recovered ACLFs (showing lower viral load) in 
comparison to healthy controls. Based on their data 
the authors suggest that a decrease in activated CD8+ 
T-cells may be related to poor outcomes in patients 
with severe hepatitis. Another observation in this 
topic is the described by Tan et al. (18) a negative cor-
relation between serum HBV DNA levels and acti-
vated CD4+HLA-DR+ cells. 
Relatively few studies have evaluated the role of 
B and NK cells in chronic hepatitis B and their re-
lation to viral load. The increased proportions of B-
cells observed by us in untreated HBV positive in-
dividuals compared to healthy controls are in ac-
cordance with the findings of Sun et al. (19). Low-
er NK cell levels in chronic HBV in comparison to 
controls (20) and a more pronounced decrease in pa-
tients with higher viral load have been reported in 
previous studies on immune cells and viral replica-
tion (10). On the contrary, no relationship between 
viral load and NK cell numbers, as well as differenc-
es between patients and normal individuals were ob-
served in our study which is consistent with the data 
of Mukherjee et al. (9). These contradicting findings 
could be partially explained by the kinetics of innate 
and adaptive immune responses in viral infections. 
Since NK cells are the first-line of immune defense 
a rise of their levels, concomitant with viral replica-
tion, could be observed in the early stage of HBV in-
fection, while with the development of adaptive im-
mune response their number may decline to normal 
values. The elevated proportion of T-cells with NK-
like activity [CD3+CD(16+56)+] found in our study 
in patients with lower viral load could be interpret-
ed as an indirect evidence of the inverse correlation 
between the serum HBV DNA levels and NKT cells, 
described by other investigators (10,21).
In conclusion, the hepatitis B virus has no di-
rect cytopathogenic effect. The liver damage and in-
volvement of other organs are consequences of the 
host immune response against the virus. The vari-
able results for immune reactivity observed in dif-
ferent investigations could be explained with the fact 
that chronic hepatitis B represents a dynamic disease 
state. However, it should be pointed that the Т-cell 
immune reactivity has a crucial role in HBV elimi-
nation. This process is mediated by CD4+ and CD8+ 
Т-cell subpopulations. Our results did not show sig-
nificant differences in Т-, В- and NK-cell response 
of patients with different viral load. Nevertheless, we 
found alterations in some of these parameters in in-
dividuals with chronic HBV infection (regardless 
of viral load) as compared to healthy controls. Our 
observations show that the cellular immune distur-
bances in CHB patients are associated with signif-
icantly decreased T-cell populations, particularly 
those with effector cell immune phenotype. 
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